Market open
Sight Sciences/$SGHT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Ticker
$SGHT
Sector
Trading on
Industry
Health Care Equipment & Supplies
Headquarters
Employees
214
Website
Sight Sciences Metrics
BasicAdvanced
$235M
Market cap
-
P/E ratio
-$1.06
EPS
2.74
Beta
-
Dividend rate
Price and volume
Market cap
$235M
Beta
2.74
52-week high
$8.45
52-week low
$1.58
Average daily volume
195K
Financial strength
Current ratio
11.012
Quick ratio
10.393
Long term debt to equity
34.228
Total debt to equity
34.228
Interest coverage (TTM)
-9.33%
Management effectiveness
Return on assets (TTM)
-19.36%
Return on equity (TTM)
-44.01%
Valuation
Price to revenue (TTM)
2.903
Price to book
2.31
Price to tangible book (TTM)
2.31
Price to free cash flow (TTM)
-6.343
Growth
Revenue change (TTM)
-2.60%
Earnings per share change (TTM)
-27.72%
3-year revenue growth (CAGR)
26.94%
3-year earnings per share growth (CAGR)
-40.32%
What the Analysts think about Sight Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Sight Sciences stock.
Sight Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Sight Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Sight Sciences News
AllArticlesVideos
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024
GlobeNewsWire·3 weeks ago
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial
GlobeNewsWire·4 weeks ago
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference
GlobeNewsWire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Sight Sciences stock?
Sight Sciences (SGHT) has a market cap of $235M as of November 08, 2024.
What is the P/E ratio for Sight Sciences stock?
The price to earnings (P/E) ratio for Sight Sciences (SGHT) stock is 0 as of November 08, 2024.
Does Sight Sciences stock pay dividends?
No, Sight Sciences (SGHT) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Sight Sciences dividend payment date?
Sight Sciences (SGHT) stock does not pay dividends to its shareholders.
What is the beta indicator for Sight Sciences?
Sight Sciences (SGHT) has a beta rating of 2.74. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.